Investors

2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015
DateTitle Download Print
06/07/18BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 ShareDownload PDFPrinter Friendly Version
06/01/18BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill SigningDownload PDFPrinter Friendly Version
05/30/18BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International ConventionDownload PDFPrinter Friendly Version
05/25/18BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation Printer Friendly Version
05/14/18BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical HighlightsDownload PDFPrinter Friendly Version
05/09/18BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in LondonDownload PDFPrinter Friendly Version
05/08/18Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14Download PDFPrinter Friendly Version
05/01/18BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering ConferenceDownload PDFPrinter Friendly Version
04/11/18BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New YorkDownload PDFPrinter Friendly Version
04/09/18Letter To ShareholdersDownload PDFPrinter Friendly Version
03/28/18BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian PatientsDownload PDFPrinter Friendly Version
03/21/18BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory BoardDownload PDFPrinter Friendly Version
03/15/18BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor ForumDownload PDFPrinter Friendly Version
03/12/18BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to ChairDownload PDFPrinter Friendly Version
03/08/18BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017Download PDFPrinter Friendly Version
03/05/18BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8Download PDFPrinter Friendly Version
02/07/18BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, CaliforniaDownload PDFPrinter Friendly Version
02/06/18BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor ConferenceDownload PDFPrinter Friendly Version
02/05/18BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of DirectorsDownload PDFPrinter Friendly Version
01/16/18BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22Download PDFPrinter Friendly Version
01/03/18BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®Download PDFPrinter Friendly Version